ERBB2 and breast cancer: After false discovery rate-bonferroni (PFDR < .05) correction, we detected 2 risk immunophenotypes of HER2-BC: human leukocyte antigen (HLA) DR on plasmacytoid DC, activated and secreting Treg %CD4+.